US Glioma - Market Insight, Epidemiology And Market Forecast - 2032

This Glioma Market - Market Insights, Epidemiology and Market Forecast- 2032 report delivers an in-depth understanding of the glioma, historical and forecasted epidemiology as well as the glioma market trends in the United States.

Glioma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted the US market size from 2019 to 2032. The report also covers current glioma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States

Study Period: 2019-2032

Glioma Disease Understanding and Treatment Algorithm

Glioma Overview

Glioma is the most common form of central nervous system (CNS) neoplasm originating from glial cells. They are very diffusely infiltrative tumors that affect the surrounding brain tissue. Three common types of gliomas are classified based on phenotypic cell characteristics: Astrocytomas, ependymomas, and oligodendrogliomas. Gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. Gliomas are further classified into Grade I-IV. Among these Grades I-IV, glioblastoma (GBM Grade IV) is the most malignant type, while pilocytic astrocytomas (Grade I) are the least malignant brain tumors. IDH1 and IDH2 are the most commonly mutated genes in low-grade glioma, with mutations estimated to occur in > 70% of cases.

Glioma Diagnosis

The diagnosis of glioma includes neurological exams (this exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes and the ability to think and remember), angiograms, magnetic resonance imaging (MRI) and computerized tomography (CT), surgical biopsy and others.

Glioma Treatment

Therapeutic management depends on the type of glioma, its size and location, and the specific characteristics of the patient. Especially in patients where the tumor cannot be entirely removed because it invades the brain in crucial areas or is not accessible, chemotherapy and radiation therapy will follow surgery. The standard treatment regimen includes surgery, chemotherapy, and radiation. Chemotherapy includes carmustine (BCNU), lomustine (CCNU), or gleostine (generic), Gliadel wafer (biodegradable discs infused with BCNU), temozolomide (TEMODAR) cisplatin, carboplatin, etoposide and irinotecan. They may be given as a single agent or in combination i.e. PCV (procarbazine, CCNU, and vincristine), carboplatin/ etoposide. The drugs most commonly used to treat brain tumors are temozolomide (TEMODAR) and bevacizumab (AVASTIN). In addition to chemotherapy, medication prescribed to individuals with gliomas includes anti-epileptic medication, anti-coagulation medication, and corticosteroids, to alleviate neurological symptoms caused by fluid accumulation around the tumor

Glioma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Glioma, Grade-specific Cases of Glioma, Age-specific Cases of Glioma, and Type-specific Cases of Glioma in the US market covering the United States from 2019 to 2032.

Key Findings

This section provides glimpse of the glioma epidemiology in the US

Country Wise- Glioma Epidemiology

• The epidemiology segment also provides the glioma epidemiology data and findings across the United States
• The Total Incident Cases of Glioma in the United States comprised of more than 19,000 cases in 2022 and are projected to increase during the forecast period
• In the United States, of all the grades, Grade IV accounted for the highest number of incident cases followed by Grade II glioma, while Grade I had the least number of cases.
• In the United States, among all the age groups, 60-74 years accounted for the highest number of glioma cases, in 2022, followed by the age-group 45-59 years
• In 2022, among all the types, glioblastoma contributed to the highest number of glioma cases, followed by diffuse astrocytoma and anaplastic astrocytoma in the United States.

Glioma Drug Chapters

Drug chapter segment of the glioma report encloses the detailed analysis of glioma marketed drugs and emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

AVASTIN: Genentech

AVASTIN (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. In December 2017, the US FDA granted full approval of bevacizumab (AVASTIN) for the treatment of adults with recurrent GBM that has progressed following prior therapy.

TEMODAR/TEMODAL: Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved TEMODAL (R) (temozolomide) Capsules for the treatment of malignant glioma.

Note: Detailed Current therapies assessment will be provided in the full report of glioma

Emerging Drugs

Ofranergene obadenovec (VB-111): VBL Therapeutics

Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGBM. Currently, the drug has completed phase III stage of clinical development for the patients with rGBM. In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan.

Trans Sodium Crocetinate: Diffusion Pharmaceuticals

Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM.

Selinexor (KPT-330): Karyopharm Therapeutics

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name XPOVIO for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision.

Vorasidenib (AG-881): Servier

Vorasidenib (AG-881), a first-in-class, dual inhibitor of mIDH1/2, was specifically developed for improved penetration across the blood-brain barrier and showed brain penetrance and reduced tumor growth in an orthotopic model of mIDH glioma. Phase I interim data suggested that both tumor-intrinsic and -extrinsic mechanisms underlie 2-HG suppression by vorasidenib and ivosidenib. Vorasidenib demonstrated a favorable safety profile and is currently being evaluated in the registration-enabling Phase III INDIGO study as a potential treatment for patients with residual or recurrent Grade II low-grade glioma.

Tovorafenib (DAY101): Day One Biopharmaceuticals

Tovorafenib (DAY101) is an investigational, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which may offer an important alternative for people with primary brain tumors or brain metastases of solid tumors. Currently, DAY101 is under evaluation in a pivotal Phase II clinical trial (FIREFLY-1) evaluating its safety and efficacy in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma (pLGG) harboring a known BRAF alteration. Based on the initial FIREFLY-1 data, the company plans to expand the development of tovorafenib as a front-line therapy for patients newly diagnosed with pLGG and anticipates reporting topline data from this trial in the first quarter of 2023, and if the data are supportive, the company expects to file an NDA to FDA, in first of half 2023.

Note: Detailed emerging therapies assessment will be provided in the final report.

Glioma Market Outlook

Glioma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The first step in treating glioma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and to remove as much tumor as possible safely. Glioma surgery is performed to achieve a “maximum safe resection,” or removing as much of the tumor as possible without causing lasting neurological damage.

It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The glioma pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and, others are some of the major players that are going to alter the market dynamics in the coming years.

Key Findings

This section includes a glimpse of the glioma the United States market.

• The total market size of glioma in the United States is more than USD 600 million in 2022 and is projected to grow during the forecast period (2022-2032).
• According to the estimates, the highest market size of glioma is from the United States, in 2022.
• In the United States, among the current therapies for glioma Optune ± TMZ captured the highest revenue in 2022.

The United States Market Outlook

The total market size of glioma in the United States is expected to increase during the study period (2019-2032).

Analyst Commentary

• The market of glioma is currently using Temozolomide (TEMODAR) and Bevacizumab (AVASTIN) as approved therapies, but the market lacks an effective strategy to cure glioma, which provides a lucrative opportunity to develop more treatment options.
• Advancement in the understanding of molecular mechanisms and gene mutations are leading to more promising and tailored therapeutic approaches for glioma patients
• Owing to the launch of Bevacizumab biosimilars, a reduction in cost burden can be witnessed
• Despite a strong pipeline, most of the emerging therapies tend to fail in the high phase trials
• There is a substantial market opportunity for vaccines and oncolytic virus therapies in glioma

Glioma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers glioma market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Kintara Therapeutics ‘VAL-083' is a DNA-targeting agent, in three distinct biomarker-driven glioma patient populations. VAL-083 can cross the blood-brain barrier (BBB), has biological and tumor affecting activity against a range of cancers, including glioma and ovarian cancer. As per our analysis VAL-083, drug uptake in the US is expected to be medium-fast with peak share of 12%, years to peak would be 7 years in first line, whereas in second-line peak share is estimated to 5.5%.

Glioma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for glioma emerging therapies.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like Chief Executive Officer, VBL Therapeutics, Chief executive officer, DNAtrix, Chief Medical Officer, VBI Vaccines, Chief Medical Officer, Kazia Therapeutics and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or glioma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs competitive and market Intelligence analysis of the glioma market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of glioma, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the glioma epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for glioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of glioma market; historical and forecasted is included in the report, covering the US drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the US glioma market.

Report Highlights

• In the coming years, glioma market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• As per the analysis, the type- specific cases of glioma include incident cases of diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, and others
• Expected Launch of potential therapies, Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and others might change the landscape in treatment of glioma.

Glioma Report Insights

• Patient Population
• Therapeutic Approaches
• Glioma Pipeline Analysis
• Glioma Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Glioma Report Key Strengths

• Ten Years Forecast
• The US Coverage
• Glioma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Glioma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT
• Attribute Analysis

Key Questions Answered

Market Insights:

• What was the glioma market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the glioma total market size as well as market size by therapies across the US during the study period (2019-2032)?
• What are the key findings pertaining to the market across the US and which country will have the largest glioma market size during the study period (2019-2032)?
• At what CAGR, the glioma market is expected to grow at the US level during the study period (2019-2032)?
• What would be the glioma market outlook across the US during the study period (2019-2032)?
• What would be the glioma market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of glioma?
• What is the historical glioma patient pool in the United States?
• What would be the forecasted patient pool of glioma at the US level?
• What will be the growth opportunities across the US with respect to the patient population pertaining to glioma?
• At what CAGR the population is expected to grow across the US during the study period (2019-2032)?

Current Treatment Scenario and Emerging Therapies:

• What are the current options for the treatment of glioma? What are the current treatment guidelines for the treatment of glioma in the US?
• How many companies are developing therapies for the treatment of glioma?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of glioma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the glioma therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for glioma and their status?
• What are the key designations that have been granted for the emerging therapies for glioma?
• What are the US historical and forecasted market of glioma?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the glioma.
• To understand the future market competition in the glioma market and Insightful review of the SWOT analysis of glioma.
• Organize sales and marketing efforts by identifying the best opportunities for glioma in the US.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for glioma market.
• To understand the future market competition in the glioma market.